Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles by Xie, Shuyu et al.
RESEARCH Open Access
Acute toxicity study of tilmicosin-loaded
hydrogenated castor oil-solid lipid nanoparticles
Shuyu Xie
1†, Fenghua Wang
1†, Yan Wang
1, Luyan Zhu
1, Zhao Dong
1, Xiaofang Wang
1, Xihe Li
2 and
WenZhong Zhou
1*
Abstract
Background: Our previous studies demonstrated that tilmicosin-loaded hydrogenated castor oil solid lipid
nanoparticles (Til-HCO-SLN) are a promising formulation for enhanced pharmacological activity and therapeutic
efficacy in veterinary use. The purpose of this work was to evaluate the acute toxicity of Til-HCO-SLN.
Methods: Two nanoparticle doses were used for the study in ICR mice. The low dose (766 mg/kg.bw) with
tilmicosin 7.5 times of the clinic dosage and below the median lethal dose (LD50) was subcutaneously
administered twice on the first and 7th day. The single high dose (5 g/kg.bw) was the practical upper limit in an
acute toxicity study and was administered subcutaneously on the first day. Blank HCO-SLN, native tilmicosin, and
saline solution were included as controls. After medication, animals were monitored over 14 days, and then
necropsied. Signs of toxicity were evaluated via mortality, symptoms of treatment effect, gross and microscopic
pathology, and hematologic and biochemical parameters.
Results: After administration of native tilmicosin, all mice died within 2 h in the high dose group, in the low dose
group 3 died after the first and 2 died after the second injections. The surviving mice in the tilmicosin low dose
group showed hypoactivity, accelerated breath, gloomy spirit and lethargy. In contrast, all mice in Til-HCO-SLN and
blank HCO-SLN groups survived at both low and high doses. The high nanoparticle dose induced transient clinical
symptoms of treatment effect such as transient reversible action retardation, anorexy and gloomy spirit, increased
spleen and liver coefficients and decreased heart coefficients, microscopic pathological changes of liver, spleen and
heart, and minor changes in hematologic and biochemical parameters, but no adverse effects were observed in
the nanoparticle low dose group.
Conclusions: The results revealed that the LD50 of Til-HCO-SLN and blank HCO-SLN exceeded 5 g/kg.bw and thus
the nanoparticles are considered low toxic according to the toxicity categories of chemicals. Moreover, HCO-SLN
significantly decreased the toxicity of tilmicosin. Normal clinic dosage of Til-HCO-SLN is safe as evaluated by acute
toxicity.
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Background
Tilmicosin is a semi-synthetic macrolide antibiotic
developed for veterinary use with properties that include
low inhibitory concentration, broad antimicrobial spec-
trum, a large distribution volume, long elimination half-
life and rapid accumulation in bovine macrophages and
mammary gland epithelial cells [1,2]. Rapid and exten-
sive penetration of tilmicosin from blood into milk, and
slow elimination from the milk were among the charac-
teristic kinetic features of the drug after intravenous and
subcutaneous administration [1]. However, acute cardiac
toxicity following intravenous injection was serious [1].
With these characteristics, subcutaneous administration
of tilmicosin would be ideal for the treatment of bovine
mastitis. However, subcutaneous administration of tilmi-
cosin was much less effective as a dry cow or lactating
cow therapeutics against Staphylococcus aureus mastitis
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may be related to inadequate therapeutic drug concen-
trations and/or an insufficient residence time of the
antibiotic in the mammary gland [5]. Repeated adminis-
trations and high dose could enhance the clinical effi-
cacy, but high doses of tilmicosin can result in acute
cardiac toxicity in cattle and severe reactions at the
injection sites such as vascular collapse and transient
swelling caused by a transient high drug concentration
[6,7]. The severity of the side effects is dose-dependent
[8].
Our previous studies demonstrated that the tilmico-
sin-loaded hydrogenated castor oil solid lipid nanoparti-
cles (Til-HCO-SLN) are a promising formulation to
enhance the pharmacological activity and therapeutic
efficacy of tilmicosin, and can decrease reactions at
injection sites [5,9]. Pharmacokinetics study after subcu-
taneous administration to mi c ed e m o n s t r a t e dt h a tS L N
significantly extended systemic circulation time,
increased the bioavailability, and decreased the maxi-
mum serum concentration of the drug [9]. Therapeutic
study in a mouse mastitis model showed that the SLN
enhanced the antibacterial activity and therapeutic effi-
cacy of tilmicosin with reduced dose and frequency of
administration [5]. Microscopic pathology study demon-
strated that SLN did not induce inflammation at the
injection site [9].
Although it is well known that SLN have good bio-
compatibility, biodegradability and tolerability, there
are limited reports on their toxicity. The available data
revealed that the toxicity of SLN depends on their phy-
sical dimensions (such as size and shape), lipid matrix,
incorporated drug and surface chemistry [10-12].
Hydrogenated castor oil (HCO) has excellent tolerabil-
ity, but HCO formulated nanoparticles could be differ-
ent. The specific physicochemical properties of
nanoparticles such as surface properties, chemical
reactivity, physical absorption ability and permeability
are different from those of the same composition bulk
materials and such properties might result in undesir-
able effects [13].
In this study, the acute toxicity of Til-HCO-SLN was
investigated in ICR mice via mortality, clinical status,
food and water consumption, body weight, gross and
microscopic pathology, and hematologic and biochem-
ical parameters.
Materials and methods
Materials
Hydrogenated castor oil was purchased from Tongliao
Tonghua Castor Chemical Co., Ltd. Tilmicosin was
obtained from Jining Medicine Corporation. Polyvinyl
alcohol (PVA) was purchased from Sigma (St. Louis,
MO, USA). HCO was used as lipid matrix and PVA was
utilized as emulsifier to prepare the nanoparticles by a
hot homogenization and ultrasonication method as
described previously [5]. The encapsulation efficiency
and loading capacity of Til-HCO-SLN was determined
using a UV spectrophotometer method as described pre-
viously [5]. The diameter, polydispersivity index and zeta
potential analysis of the nanoparticles was performed by
photon correlation spectroscopy using Zetasizer Nano
ZS90 (Malvern Instruments) [5]. The residual PVA of
Til-HCO-SLN was determined by a colorimetric method
[9]. The encapsulation efficiency, loading capacity, dia-
meter, polydispersivity index, zeta potential and residual
PVA of Til-HCO-SLN were 59.82 ± 5.16%, 9.97 ±
0.86%, 334 ± 44 nm, 0.49 ± 0.04, -5.72 ± 0.34 mV and
0.35 ± 0.03%, respectively. Blank HCO-SLN had particle
size 369 ± 54 nm, PDI 0.35 ± 0.05, zeta potential -11.46
± 1.01 mV, and residual PVA 0.32 ± 0.04%. Other che-
micals and reagents not specified in the text were of
analytical grade or equivalent.
Animals
ICR mice of each sex (20-22 g) were obtained from Vital
River Beijing (Beijing, China). The animals were housed
at room temperature under natural day and night cycles
with free access to water and food. They were kept for
one week before use. All experimental protocols con-
cerning the handling of mice were in accordance with
the requirements of the Institutional Animal Care and
Use Committee at China Agricultural University.
Experimental design
Eighty mice were randomly divided into 8 groups with 5
male and 5 female animals in each group. Two SLN
doses were used in the experiment. The high dose of 5
g/kg.bw (equivalent to tilmicosin 540 mg/kg.bw) was
given once on the first day. The low dose of 766 mg/kg.
bw (equivalent to tilmicosin 75 mg/kg.bw) was given
twice on the first and 7th day. The Til-HCO-SLN was
suspended in 500 μl sterilized saline and subcutaneously
administered on the dorsum of mice. The same amount
of blank HCO-SLN and native tilmicosin suspended or
dissolved in 500 μl sterilized saline and also the same
volume of sterilized saline were subcutaneously adminis-
tered in different control groups.
Clinical sign observation
After medication, the mice were observed over a 14 day
period. The symptoms of toxicity such as mortality,
spirit, behavior, and appetite as well as body weight
were record daily.
Necropsy
At the end of the experiment, blood samples were col-
lected from the eye vein for biochemical and
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to evaluate the gross internal abnormalities viz. organ
coefficients (relative organ weight) and appearance of
heart, lung, liver, spleen and kidneys. The organ coeffi-
cients were calculated [14]:
Organ coefﬁcients =

Weight of organ

g

/Body weight

g

× 100%
Histopathological study
The heart, liver, lung, spleen and kidneys were fixed in
4% formalin and embedded in paraffin. Sections of 5 μm
thick were cut and placed onto glass slides. After stain-
ing with hematoxylin and eosin, histopathological
changes were observed using optical microscope (Olym-
pus IX71, Japan).
Biochemical assays
The blood samples were centrifuged at 3000 rpm for 10
min using Sigma centrifuge (Sigma1-14, Germany).
Serum levels of alanine aminotransferas (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP),
cholesterol esters (CHOL), total proteins (TP), albumin
(ALB), globulin (GLB), total bilirubin (TBIL), blood urea
nitrogen (BUN), creatinine (CREA) and glucose (GLU)
were measured with a biochemical autoanalyzer (Type
7170, Hitachi, Japan) [15,16].
Hematological study
Levels of white blood cells (WBC), red blood cells
(RBC), haematocrit (HCT), mean corpuscular volume
(MCV), hemoglobin (HGB), mean corpuscular haemo-
globin (MCH), mean corpuscular haemoglobin concen-
tration (MCHC), neutrophils (NEU), lymphocytes(LYM),
monocytes (MON), eosinophils (EOS), basophils (BAS),
blood platelet (PLT), plateletcrit (PCT), mean platelet
volume (MPV) and red cell distribution width (RDW)
were determined by an automatic hematology analyzer
(ABX, Pentra 60, France) [17,18].
Statistical analysis
Results were expressed as mean ± standard deviation (S.
D.) and were compared by one-way analysis of variance
(ANOVA) using Statistical Product and Service Solutions
(SPSS) V13.0 (SPSS Inc., Chicago, IL, USA). The differ-
ences were considered statistically significant at the level
of P < 0.05.
Results
Clinical signs and mortality
Table 1 shows the ratio of animals with clinical signs
and the mortality after the different treatments. After
administration with the high dose, all mice treated with
native tilmicosin died within 2 h. In contrast, no mice
died in Til-HCO-SLN group during the observed period.
There were no obvious adverse responses except for the
transient reversible action retardation, anorexy and
gloomy spirit within 48 h. In the blank HCO-SLN
group, all mice survived and the clinical signs were simi-
lar to those in the Til-HCO-SLN group.
At the low dose, Til-HCO-SLN and blank HCO-SLN
did not cause mortality and any apparent toxicity such
as abnormal spirit and behaviors. The low dose of native
tilmicosin induced action retardation, incoordination,
accelerated breath and gloomy spirit immediately after
the first administration, and two male and one female
died within 2 h. The spirit and behavior of surviving
mice were gradually recovered. Ten min after the sec-
ond administration, the mice displayed accelerated
breath and gloomy spirit, and stayed together, not will-
i n gt om o v e .O n em a l ea n do n ef e m a l em o u s ed i e d
within 2 h and the survived mice recovered gradually.
Growth rate
Figure 1 shows the cumulative growth rates of mice. At
the high dose, the cumulative growth rate of Til-HCO-
SLN group was negative and significantly lower than the
saline control group within 3 days post treatment. Three
days later, the growth rate increased to the same level as
Table 1 The ratio of animals with clinical signs and the mortality after different treatment
Compound Dose (mg/kg.bw)
SLN/Tilmicosin
Animal number
(Male/Female)
Animals with clinical sign/treated animals Died animals/treated animals
Male Female Male Female
Til-HCO-SLN 5000/540 5/5 5/5 5/5 0/5 0/5
Til-HCO-SLN* 766/75 5/5 0/5ab 0/5ab 0/5ab 0/5ab
HCO-SLN 5000/0 5/5 5/5 5/5 0/5 0/5
HCO-SLN* 766/0 5/5 0/5ab 0/5ab 0/5ab 0/5ab
Tilmicosin -/540 5/5 5/5 5/5 5/5 5/5
Tilmicosin* -/75 5/5 5/5a, 3/3b 5/5a, 4/4b 2/5a, 1/3b 1/5a, 1/4b
Saline -/- 5/5 0/5 0/5 0/5 0/5
Saline* -/- 5/5 0/5ab 0/5ab 0/5ab 0/5ab
* Animal treated twice on the first and 7th day: (a) after first injection; (b) after second injection.
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in blank HCO-SLN group. At the low dose, no signifi-
cant differences of cumulative growth rates were found
in Til-HCO-SLN, blank HCO-SLN, native tilmicosin
and saline groups.
Food and water consumption
Daily food and water consumption is shown in Figure 2.
After administration of the high dose, the mice in Til-
HCO-SLN and blank HCO-SLN groups hardly eat food or
drink water during the first day, but they gradually recov-
ered foraging. Daily water and food consumption comple-
tely recovered by the second and fifth day, respectively.
With the low dose medication, the adverse effect of
reduced food intake was similar as for high dose but to a
lower extent. Daily food and water consumption in Til-
HCO-SLN group was much similar to that in blank HCO-
SLN group. The two nanoparticle groups showed almost
the same levels of daily food and water consumption as
the control saline group except for the 1st and 8th injec-
tion days on which the food and water consumption was
less compared with the saline control group.
Organ appearances and coefficients
Necropsy at the end of the experiment (day 14) did not
show any macroscopic organ changes in Til-HCO-SLN
and other control groups with either high or low doses.
With the high dose, slight increases of liver and spleen
coefficients were observed in Til-HCO-SLN and blank
HCO-SLN groups, while the heart coefficient was
slightly decreased in Til-HCO-SLN group (Table 2).
With the low dose, the coefficients of heart, liver,
spleen, lung and kidneys were not significantly different
among the Til-HCO-SLN, blank HCO-SLN, native til-
micosin and saline groups (Table 2).
Histopathology
With the high dose, both Til-HCO-SLN and blank
HCO-SLN induced histopathological changes in liver,
spleen and heart, while the changes in blank HCO-SLN
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Figure 1 Cumulative growth rates of mice after treatment.
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Figure 2 Daily food and water consumption of mice after
treatment. A: Daily food consumption; B: Daily water consumption.
Xie et al. Particle and Fibre Toxicology 2011, 8:33
http://www.particleandfibretoxicology.com/content/8/1/33
Page 4 of 10Table 2 Coefficients of heart, liver, spleen, lung and kidneys (Mean ± S.D., n = 10).
Compound Heart Liver Spleen Lung Kidneys
Saline H 0.602 ± 0.134 4.536 ± 0.632 0.333 ± 0.063 0.657 ± 0.105 1.333 ± 0.134
L 0.594 ± 0.051 5.038 ± 0.534 0.368 ± 0.075 0.720 ± 0.121 1.689 ± 0.271
Blank HCO-SLN H 0.583 ± 0.070 5.063 ± 0.453
b 0.447 ± 0.124
b 0.626 ± 0.109 1.364 ± 0.214
L 0.642 ± 0.067 4.787 ± 0.813 0.426 ± 0.045 0.732 ± 0.161 1.661 ± 0.420
Til-HCO-SLN H 0.477 ± 0.076
a 5.072 ± 0.493
a 0.425 ± 0.100
a 0.629 ± 0.147 1.305 ± 0.226
L 0.618 ± 0.076 4.405 ± 0.877 0.395 ± 0.075 0.732 ± 0.119 1.659 ± 0.222
Native Tilmicosin L 0.662 ± 0.030 4.740 ± 0.600 0.359 ± 0.076 0.707 ± 0.078 1.548 ± 0.192
a Significant difference between Til-HCO-SLN and saline treated mice, p < 0.05.
b Significant difference between blank HCO-SLN and saline treated mice, p < 0.05.
H: high dose; L: low dose.
Figure 3 Organ histopathological picture of mice treat with the high dose (H&E, magnification ×200). Liver histopathological pictures of
mice treated with sterilized saline (A), Til-HCO-SLN (B) and blank HCO-SLN (C); Spleen histopathological pictures of mice treated with sterilized
saline (D), Til-HCO-SLN (E) and blank HCO-SLN (F); Heart histopathological pictures of mice treated with sterilized saline (G), Til-HCO-SLN (H) and
blank HCO-SLN (I); Lung histopathological pictures of mice treated with sterilized saline (J), Til-HCO-SLN (K) and blank HCO-SLN (L); Kidney
histopathological pictures of mice treated with sterilized saline (M), Til-HCO-SLN (N) and blank HCO-SLN (O).
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tion in liver includes swelling, degeneration, necrosis of
certain amounts of hepatocytes around the central vein,
and obscure lobular boundaries. The spleen displayed
dwindling of splenic corpuscle and reducing of the sple-
nic lymphocytes. Degeneration and necrosis of cardiac
cells and necrosis and breakage of cardiac muscle fibers
were observed in the heart.
After low dose injection, no observable pathological
changes were found in heart, liver, lung, kidneys and
spleen (Figure 4).
Biochemistry index
Biochemistry study showed that at the high dose there
were some changes of some biochemical parameters in
both the Til-HCO-SLN and blank HCO-SLN groups
compared with the saline group, but the biochemical
parameter values were at similar levels and the differ-
ences were very slight (Table 3). At the low dose, no
statistical change of biochemical parameters was
observed in Til-HCO-SLN treated, as well as blank
HCO-SLN and native tilmicosin treated mice compared
with saline treated controls (Table 3).
Figure 4 Organ histopathological picture of mice treat with the low dose (H&E, magnification ×200). Liver histopathological pictures of
mice treated with sterilized saline (A), Til-HCO-SLN (B) and blank HCO-SLN (C); Spleen histopathological pictures of mice treated with sterilized
saline (D), Til-HCO-SLN (E) and blank HCO-SLN (F); Heart histopathological pictures of mice treated with sterilized saline (G), Til-HCO-SLN (H) and
blank HCO-SLN (I); Lung histopathological pictures of mice treated with sterilized saline (J), Til-HCO-SLN (K) and blank HCO-SLN (L); Kidney
histopathological pictures of mice treated with sterilized saline (M), Til-HCO-SLN (N) and blank HCO-SLN (O).
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The hematological parameters in Til-HCO-SLN group
had no obvious changes compared with the saline con-
trol group with both the high and low doses (Table 4).
At the high dose, there were some statistical differences
of hematological parameters between the blank HCO-
SLN and saline groups, but the differences were slight
(Table 4).
Discussion
Acute toxicity values such as LD50 and symptoms of
treatment effect are often used as the basis for classify-
ing chemicals into toxicity categories, and their subse-
quent regulation [19,20]. In this study, two
nanoparticle doses were used to evaluate the acute
toxicity of Til-HCO-SLN. The high dose was 5 g/kg b.
w, which is the highest dose in an acute toxicity study
according to the guidelines for toxicity testing [20,21].
The low nanoparticle dose of 766 mg/kg.bw, equivalent
to 75 mg/kg.bw tilmicosin, was chosen based on the
clinic dosage and the median lethal dose (LD50). If the
overdose did not induce treatment effect, the clinic
dosage should be safe. At the same time, the main
focus of the low dose was on observing the treatment
symptoms rather than on determining the mortality,
and thus the dose was below the LD50°The LD50 of til-
micosin for subcutaneous administration is 97 mg/kg
in male ICR mice and 109 mg/kg.bw in female ICR
mice [22].
The results showed that Til-HCO-SLN and blank
HCO-SLN was not lethal to mice with the high dose,
suggesting that the Til-HCO-SLN and blank HCO-SLN
are classified as low-toxic substances according to the
toxicity categories of chemicals [23]. This is mainly
attributed to the good biocompatibility and biodegrad-
ability of the lipid matrix and the emulsifier. HCO can
be hydrolyzed in vivo resulting in the formation of fatty
acid and glycerin as metabolites [24]. PVA can be
degraded into acetic acid by oxidase and hydrolase
enzyme [25]. The oral LD50 is in the range of 15-20 g/
kg [25], while the residual PVA of Til-HCO-SLN and
blank HCO-SLN was very low.
Table 3 Biochemical parameters of treated mice (Mean ± S.D., n = 10).
Parameters Saline Til-HCO-SLN Blank HCO-SLN Tilmicosin (n = 5)
AST (U/L) H 147.78 ± 37.78 157.20 ± 34.95 150.20 ± 24.15
L 152.14 ± 18.77 143.29 ± 19.79 150.00 ± 16.12 171.00 ± 17.15
ALT (U/L) H 44.56 ± 17.37 37.11 ± 9.18 41.00 ± 10.79
L 42.86 ± 8.28 47.14 ± 11.05 49.57 ± 7.28 50.75 ± 0.96
ALT/AST H 0.30 ± 0.04 0.26 ± 0.06 0.27 ± 0.05
L 0.29 ± 0.06 0.33 ± 0.07 0.33 ± 0.05 0.30 ± 0.03
ALP (U/L) H 136.44 ± 34.46 150.60 ± 19.57 140.29 ± 21.47
L 121.71 ± 22.89 111.14 ± 19.30 121.50 ± 27.77 135.25 ± 17.00
TBIL (umol/L) H 2.56 ± 1.43 1.86 ± 0.94 1.81 ± 0.89
L 0.90 ± 0.42 0.74 ± 0.35 1.09 ± 0.41 1.38 ± 1.05
CHOL (mmol/L) H 3.86 ± 0.48 4.21 ± 0.89 3.81 ± 0.92
L 3.53 ± 0.54 3.54 ± 0.62 3.69 ± 0.74 3.67 ± 0.44
CREA (umol/L) H 11.60 ± 3.27 13.13 ± 1.73 11.80 ± 2.53
L 18.29 ± 4.57 18.00 ± 3.42 18.25 ± 1.91 17.25 ± 0.96
BUN (mmol/L) H 7.53 ± 1.96 7.00 ± 1.12 6.72 ± 1.11
L 8.59 ± 1.54 9.54 ± 1.48 9.47 ± 1.79 9.70 ± 0.58
TP (g/L) H 60.90 ± 2.77 60.80 ± 2.57 56.00 ± 3.02
b
L 61.31 ± 3.57 59.37 ± 1.86 60.69 ± 2.81 61.03 ± 2.16
ALB (g/L) H 41.49 ± 1.60 40.44 ± 2.13 38.34 ± 1.26
b
L 38.09 ± 4.89 37.06 ± 5.21 36.56 ± 3.35 38.90 ± 4.22
GLB (g/L) H 19.41 ± 1.45 20.36 ± 1.31 17.66 ± 2.01
b
L 23.21 ± 2.18 22.31 ± 3.94 24.13 ± 2.70 22.13 ± 2.81
ALB/GLB H 2.14 ± 0.12 1.99 ± 0.16
a 2.19 ± 0.19
L 1.71 ± 0.34 1.84 ± 0.46 1.74 ± 0.31 1.80 ± 0.41
GLU (mmol/L) H 6.07 ± 1.68 5.98 ± 1.27 6.33 ± 1.45
L 5.18 ± 1.78 5.02 ± 1.51 4.95 ± 1.18 5.78 ± 0.57
a Significant difference between Til-HCO-SLN and saline treated mice, p < 0.05.
b Significant difference between blank HCO-SLN and saline treated mice, p < 0.05.
Abbreviations: H: high dose; L: low dose; AST: aspartate aminotransferase; ALT: serum alanine aminotransferas; ALP: alkaline phosphatase; TBIL: total bilirubin;
CHOL: cholesterol esters; CREA: creatinine; BUN: blood urea nitrogen; TP: total proteins; ALB: albumin; GLB: globulin; GLU: glucose.
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induced some slight intoxication signs of transient
reversible abnormal clinic symptoms. The liver and
spleen were affected as indicated by the organ coeffi-
cients and pathological changes, which is in agreement
with other report that high doses of SLN could lead to
accumulation of the lipid in liver and spleen and subse-
quently to pathological alterations [10]. This might be
due to that liver and spleen are the two dominant
organs for distribution and metabolism of SLN [26,27].
The damage of liver function is also confirmed by some
biochemical parameter changes. Til-HCO-SLN caused
slight decrease of the albumin (ALB)/globulin (GLB),
while blank HCO-SLN leads to minor reduction of ALB
and GLB. The hepatocellular damage is often indicated
by changes of albumin, globulins and total protein [28].
However, other liver function related parameters such
as alanine aminotransferas (ALT), aspartate aminotrans-
ferase (AST), ALT/AST, bilirubin and urea were normal,
suggesting that the damage of liver was slight and rever-
sible [26]. In addition, Til-HCO-SLN induced heart
coefficient and histopathological changes, while blank
HCO-SLN resulted in no coefficient change and much
less histopathological alteration. This could be due to
the acute cardiac toxicity of tilmicosin [22].
With low dose, the mice in the Til-HCO-SLN and
blank HCO-SLN groups did not display any intoxication
syndrome as referenced with the high dose groups. All
Table 4 Hematological parameters of treated mice (Mean ± S.D., n = 10).
Parameters Saline Til-HCO-SLN Blank HCO-SLN Tilmicosin (n = 5)
WBC (10
9/L) H 5.51 ± 1.55 5.52 ± 1.68 4.95 ± 1.39
L 5.89 ± 1.80 5.05 ± 1.06 5.22 ± 0.93 5.16 ± 0.78
RBC H 8.56 ± 1.30 7.58 ± 1.40 7.07 ± 1.14
b
(10
12/L) L 9.64 ± 0.79 9.58 ± 0.96 9.63 ± 0.56 9.08 ± 0.69
HCT (L/L) H 0.44 ± 0.05 0.40 ± 0.03 0.36 ± 0.05
b
L 0.59 ± 0.09 0.61 ± 0.07 0.58 ± 0.06 0.57 ± 0.07
MCV (fL) H 51.01 ± 2.69 51.06 ± 2.10 51.72 ± 4.05
L 60.37 ± 5.74 63.18 ± 4.22 60.63 ± 5.34 62.47 ± 4.76
HGB (g/L) H 141.44 ± 10.48 129.89 ± 10.25 119.43 ± 15.80
b
L 153.63 ± 9.97 155.00 ± 12.00 153.38 ± 6.02 147.80 ± 4.21
MCH (pg) H 16.84 ± 2.33 16.44 ± 1.67 16.99 ± 1.77
L 15.96 ± 0.46 16.21 ± 0.57 15.94 ± 0.54 16.30 ± 0.80
MCHC (g/L) H 329.33 ± 32.11 320.70 ± 22.14 328.00 ± 19.47
L 266.88 ± 29.78 257.13 ± 15.75 264.50 ± 23.68 262.40 ± 27.93
PLT (10
9/L) H 873.89 ± 139.28 812.29 ± 157.35 802.00 ± 154.55
L 971.13 ± 145.25 967.63 ± 171.96 925.88 ± 219.88 972.60 ± 233.96
MPV (fL) H 6.74 ± 1.78 6.50 ± 1.14 6.25 ± 1.16
L 5.43 ± 0.29 5.28 ± 0.21 5.25 ± 0.22 5.32 ± 0.38
PCT (L/L) H 0.57 ± 0.21 0.47 ± 0.10 0.40 ± 0.11
b
L 0.53 ± 0.07 0.57 ± 0.09 0.55 ± 0.11 0.56 ± 0.06
RDW (fL) H 11.83 ± 3.81 11.70 ± 2.28 11.75 ± 1.74
L 17.21 ± 0.79 18.00 ± 1.90 17.47 ± 2.02 17.72 ± 1.37
NEU (%) H 14.75 ± 2.02 15.70 ± 2.22 17.83 ± 1.50
L 15.96 ± 5.04 20.06 ± 5.33 18.99 ± 3.12 20.44 ± 5.95
LYM (%) H 84.25 ± 2.78 81.64 ± 3.94 80.63 ± 1.32
L 80.71 ± 5.68 74.93 ± 5.84 76.43 ± 4.69 76.88 ± 6.40
MON (%) H 0.85 ± 0.07 1.73 ± 1.13 1.30 ± 0.36
L 2.84 ± 1.03 4.30 ± 1.77 3.85 ± 1.73 2.24 ± 1.18
EOS (%) H 0.20 ± 0.08 0.23 ± 0.19 0.15 ± 0.10
L 0.26 ± 0.17 0.40 ± 0.13 0.33 ± 0.10 0.16 ± 0.11
BAS (%) H 0.17 ± 0.10 0.24 ± 0.14 0.18 ± 0.16
L 0.23 ± 0.07 0.31 ± 0.22 0.41 ± 0.29 0.28 ± 0.15
a Significant difference between Til-HCO-SLN and saline treated mice, p < 0.05.
b Significant difference between blank HCO-SLN and saline treated mice, p < 0.05.
Abbreviations: H: high dose; L: low dose; WBC: white blood cells; RBC: red blood cells; HCT: haematocrit; MCV: mean corpuscular volume; HGB: hemoglobin; MCH:
mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; PLT: blood platelet; MPV: mean platelet volume; PCT: plateletcrit; RDW: red
cell distribution width; NEU: neutrophils; LYM: lymphocytes; MON: monocytes; EOS: eosinophils; BAS: basophils.
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Page 8 of 10mice survived and showed no clinic symptoms of treat-
ment. There were no changes of organ appearance,
organ coefficient, histopathology, biochemical and hae-
matological parameters. The transient decrease of daily
food and water consumption after the injections on the
1st and 8th days could be due to the irritation of the
drug [29]. These results indicate that the nanoparticle
carrier and the formulation were safe at 7.5 times of the
clinic dosage.
After administration with native tilmicosin, all mice
in the high dose group died within 2 h. The surviving
mice in the low dose group showed action retardation,
incoordination, accelerated breath and gloomy spirit
within 2 h after each administration. Tilmicosin primar-
ily affects the heart, leading to acute heart failure with
clinical signs of depression, increased heart rate, pul-
monary edema, and death [22,30]. Tilmicosin did not
influence the organ appearance and coefficients, bio-
chemical and hematological parameters at the low dose.
The intoxication symptoms could be too low to observe.
Another reason might be that the acute toxicity of tilmi-
cosin was temporary [31], and all the functions were
recovered at the end of experiments. In contrast, all
mice survived and showed no treatment adverse effect
in Til-HCO-SLN group with the low dose. These results
demonstrated that this nanoparticle carrier remarkably
reduced the acute toxicity of tilmicosin. The lower tran-
sient drug concentration of Til-HCO-SLN could
account for the reduction of acute toxicity of tilmicosin
[7,8].
Conclusion
The HCO-SLN is low toxic judged by the LD50 although
clinical symptoms indicated some toxicity. This nano-
particle carrier can significantly decrease the toxicity of
tilmicosin. Normal clinic dosage of Til-HCO-SLN is safe
as evaluated by acute toxicity. The subchronic and
c h r o n i ct o x i c i t yo fT i l - H C O - S L Nn e e dt ob ef u r t h e r
studied.
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Til-HCO-SLN: tilmicosin-loaded hydrogenated castor oil solid lipid
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blood platelet; MPV: mean platelet volume; PCT: plateletcrit; RDW: red cell
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EOS: eosinophils; BAS: basophils.
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